Contact Us
Drug Search Results
More Filters [+]

Oteracil

Alternative Names: oteracil
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | China | Cyprus | Denmark | Estonia | Germany | Hong Kong | Hungary | Indonesia | Japan | Malaysia | Netherlands | Norway | Russia | Spain | Taiwan | Thailand | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Taiko Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oteracil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Pancreatic Cancer

Phase 3: Gastrointestinal Cancer|Breast Cancer

Phase 2: Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Breast Cancer|Bile Duct Cancer|Cervical Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Pancreatic Cancer|Uterine Cancer|Colorectal Cancer|Esophageal Cancer|Adenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2024-SR-233

P2

Not yet recruiting

Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer

2027-05-01

ZF-2023-387-01

P2

Not yet recruiting

Colorectal Cancer

2027-03-21

HMPL-013-FLAG-E102

P2

Not yet recruiting

Esophageal Cancer|Squamous Cell Carcinoma

2026-06-10

Stars

P2

Recruiting

Esophageal Cancer|Squamous Cell Carcinoma

2025-04-01

Recent News Events

Date

Type

Title

05/14/2024

PubMed

 Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer.

05/11/2024

PubMed

 A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma.

05/05/2024

PubMed

 Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.

01/31/2022

News Article

 European Commission approves Teysuno in metastatic colorectal cancer

01/04/2022

News Article

 Positive EMA opinion for the use of Teysuno in metastatic colorectal cancer

09/03/2020

News Article

 Small Molecule Cancer Drugs Industry Report 2020-2026 - Clinical Trials Insight on >2,500 Drugs by Phase, Company, Country, Formulation and Indication

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions